Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexuprazan-based 10-day concomitant therapy for first-line Helicobacter pylori eradication
KCT0009116Phase 4Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fexuprazan, clarithromycin, amoxicillin, metronidazole in Helicobacter pylori infection, sponsored by Daewoong Pharmaceutical. Started May 2024; status: completed.
02
Drugs
fexuprazanclarithromycinamoxicillinmetronidazole
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on KCT0009116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009116.